A good article. POH did well, opening line ACL,SPL,POH. with POH and SPL attracting overseas money and SI's.
Expecting the stronger companies to go well, POH fits well, cash on hand nearing commercialisation. $200 m from one fund picking 10 -12 select companies will push others also.
There will be a multiplier effect of this money, so appreciation in SP for solid bios will be significant.
If POH's flagged Global Deal produces a cash profit, the rerating will be substantial to join the ranks of the 7 or 8 profitable companies.
The potential for an OXY deal that dwarfs ACR testosterone deal is strong. All in all we fit well in the framework of that articles view of our part of the investment world.
biotech spread in the afr, page-5
Add AVE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.3¢ |
Change
0.001(20.0%) |
Mkt cap ! $9.507M | |||
| Open | High | Low | Value | Volume |
| 0.3¢ | 0.3¢ | 0.3¢ | $408 | 154.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 61 | 90794613 | 0.2¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.3¢ | 54998583 | 13 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| AVE (ASX) Chart |